Sequence: Poly(γ-(4-vinylbenzyl)-L-glutamate) derivative; DP ~206 (helical polypeptide)
| Experiment Id | EXP000236 |
|---|---|
| Paper | Suppression of Hepatic Inflammation via Systemic siRNA Delivery by Membrane-Disruptive and Endosomol |
| Peptide | PPABLG |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | 50–500 µg siRNA/kg (i.v.) |
| Rna Concentration | 50–500 µg siRNA/kg |
| Mixing Ratio | 20/2/1 (w/w/w) |
| Formulation Format | hybrid polypeptide nanoparticle (HNP) |
| Formulation Components | PPABLG + PAOBLG-MPA + siRNA |
| Size Nm | 100.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Mouse LPS/D-GalN–induced hepatic inflammation model |
| Administration Route | intravenous |
| Output Type | therapeutic gene silencing and survival |
| Output Value | Systemic TNF-α knockdown; reduced cytokines; 50% survival at 50 µg/kg |
| Output Units | |
| Output Notes | Kupffer-cell–targeted delivery; strong anti-inflammatory rescue |
| Toxicity Notes | Low immune and systemic toxicity |
| Curation Notes |